200.71
+0.83%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Wanbury
Its shares trade on NSE under the ticker WANBURY.NS. It has been listed since 24 February 1992. In the fiscal year to 31 March 2026, it reported revenue of ₹6.50bn and net income of ₹661.3m. At that date it held total assets of ₹5.18bn and shareholders' equity of ₹1.44bn.
Wanbury Ltd. engages in the business of pharmaceutical and related activities, including research. The company is headquartered in Navi Mumbai, Maharashtra. The firm is engaged in the business of pharmaceutical and related activities, including research. The firm operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. The company has approximately 13 API products. The company manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The firm's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 24 Feb 1992
- Employees
- 1,582
- Website
- wanbury.com ↗
Leadership
Pay as last reported
- Mr. K. ChandranVice Chairman of the Board, since 2015₹2.8m
- Mr. Vinod VermaChief Financial Officer
- Mr. Jitendra GandhiCompliance Officer, Company Secretary
- Mr. Manojkumar Khubchand GursahaniNon-Executive Independent Director
- Mr. Mridul MehtaNon-Executive Independent Director
- Ms. Anupama VaidyaNon-Executive Independent Director₹125,000
- Mr. Pallavur Sankar Dass VaidyanathanAdditional Non-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Wanbury Ltd. produces Metformin with over 8500 tons annually for diabetes treatment.
- Wanbury has 13 API products including Metformin HCL and Sertraline for mental health.
- Wanbury operates through API and Domestic Formulations divisions in Navi Mumbai, India.
Weaknesses
- Wanbury's API Business relies on Metformin and Sertraline as key products.
- Wanbury's subsidiaries are located in Netherlands, UAE, China, and Spain for global operations.
- Wanbury has 1582 employees with no mention of R&D investment in the facts.
Opportunities
- Wanbury can expand API products to include Glucosamine and Mefenamic Acid in new markets.
- Wanbury's subsidiaries in China and Spain offer potential for regional market growth.
- Wanbury's Domestic Formulations Business can leverage Sertraline for mental health treatment expansion.
Threats
- Wanbury faces competition from other pharmaceutical companies in the API market.
- Wanbury's reliance on Metformin for diabetes treatment may limit market diversification.
- Wanbury's subsidiaries in China and Spain could face regulatory challenges in those regions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.